Business Wire04.24.20
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin blood culture collection sets, has received 510(k) clearance (k191832) from the U.S. Food and Drug Administration (FDA) for its novel push-button needle.
“The FDA clearance of our push-button needle is another important step in the continued growth of our company,” said Bob Rogers, CEO of Kurin. “Development of our proprietary needle provides us vertical integration and also allows us to offer superior options to our customers. We are experiencing exponential growth and milestones like this one position Kurin well for our rapid expansion plans.”
Kurin developed initial specimen discard technology that automatically and passively sidelines potential contaminants during blood culture collection. When skin microbes enter into blood culture samples, false positive test results may misinform physicians and lead to unnecessary medical treatment and risk for patients, as well as significant costs for the hospital. Kurin’s patented automatic blood discard product is the only FDA 510(k) cleared blood culture product in its class.
Earlier this week, Kurin announced that it has been awarded a contract for the Kurin Lock, a blood culture optimization device designed to reduce contamination rates. Effective April 1, the new agreement offers Vizient members negotiated pricing and terms.
“We are pleased to have this agreement with Vizient,” said Rogers. “Several Vizient member hospitals have already benefitted from sustained results in reducing their blood culture contamination rates with Kurin and formalizing this agreement will help additional hospitals add Kurin to their important work in protecting patients from harm. By providing this innovative solution at contracted pricing, Vizient and Kurin are helping to reduce overall healthcare costs.”
Vizient is the largest member-driven performance improvement company in the country. Vizient’s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and nonacute health care providers.
“The FDA clearance of our push-button needle is another important step in the continued growth of our company,” said Bob Rogers, CEO of Kurin. “Development of our proprietary needle provides us vertical integration and also allows us to offer superior options to our customers. We are experiencing exponential growth and milestones like this one position Kurin well for our rapid expansion plans.”
Kurin developed initial specimen discard technology that automatically and passively sidelines potential contaminants during blood culture collection. When skin microbes enter into blood culture samples, false positive test results may misinform physicians and lead to unnecessary medical treatment and risk for patients, as well as significant costs for the hospital. Kurin’s patented automatic blood discard product is the only FDA 510(k) cleared blood culture product in its class.
Earlier this week, Kurin announced that it has been awarded a contract for the Kurin Lock, a blood culture optimization device designed to reduce contamination rates. Effective April 1, the new agreement offers Vizient members negotiated pricing and terms.
“We are pleased to have this agreement with Vizient,” said Rogers. “Several Vizient member hospitals have already benefitted from sustained results in reducing their blood culture contamination rates with Kurin and formalizing this agreement will help additional hospitals add Kurin to their important work in protecting patients from harm. By providing this innovative solution at contracted pricing, Vizient and Kurin are helping to reduce overall healthcare costs.”
Vizient is the largest member-driven performance improvement company in the country. Vizient’s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and nonacute health care providers.